Measuring patient-reported outcomes in solid organ transplant recipients: An overview of instruments developed to date

PharmacoEconomics

Volumn 25, Issue 4, 2007, Pages 269-286

  Cleemput, Irina ^a   Dobbels, Fabienne ^b  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISONE;

CONSTRUCT VALIDITY; GRAFT RECIPIENT; HEALTH SURVEY; HUMAN; ORGAN PRESERVATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SOCIAL STATUS; SYSTEMATIC REVIEW;

HUMANS; PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; TRANSPLANTS; TREATMENT OUTCOME;

EID: 34247212911     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725040-00002     Document Type: Review

References (86)

1. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9 (12): 1231-43
2. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004; 43 (5): 787-93
3. Kirklin JK, McGiffin DC, Pinderski LJ, et al. Selection of patients and techniques of heart transplantation. Surg Clin North Am 2004; 84 (1): 257-xii
4. Taylor DO, Edwards LB, Boucek MM, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report 2004. J Heart Lung Transplant 2004; 23 (7): 796-803
5. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report 2004. J Heart Lung Transplant 2004; 23 (7): 804-15
6. Eurotransplant International Foundation. Eurotransplant International Foundation annual report 2005. Leiden, The Netherlands: Eurotransplant International Foundation, 2005 [online]. Available from URL: http://www.eurotransplant.nl/files/annu al_report/AR2005_def.pdf [Accessed 2007 Mar 7]
7. Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63 (10): 1435-40
8. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 (9): 847-58
9. Andreassen AK, Hartmann A, Offstad J, et al. Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 1997; 29 (6): 1324-31
10. Holm T, Andreassen AK, Aukrust P, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J 2001; 22 (5): 428-36
11. Pethig K, Heublein B, Wahlers T, et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004; 23 (1): 61-6
12. Vivekananthan K, Kalapura T, Mehra M, et al. Usefulness of the combined index of systolic and diastolic myocardial performance to identify cardiac allograft rejection. Am J Cardiol 2002; 90 (5): 517-20
13. Institute of Medicine, Committee on Health and Behavior: Research, Practice and Policy, Board on Neuroscience and Behavioral Health. Health and behavior: the interplay of biological, behavioral and societal influences. Washington, DC, National Academy Press, 2001 [online]. Available from URL: http://books.nap.edu/openbook.php?record_id=9838&page=r1 [Accessed 2007 Mar 7]
14. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270 (15): 1819-25
15. World Health Organization. Innovative care for chronic conditions: building blocks for action. Geneva: World Health Organization, 2002
16. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937-52
17. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11 (3): 193-205
18. Joseph JT, Baines LS, Morris MC, et al. Quality of life after kidney and pancreas transplantation: a review. Am J Kidney Dis 2003; 42 (3): 431-45
19. Rodes J, Navasa M. Liver transplantation and quality of life. Can J Gastroenterol 2000; 14 (8): 693-9
20. De Geest S, Dobbels F, Fluri C, et al. Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 2005; 20 (5 Suppl.): S88-98
21. Cupples SA, Stilley CS. Cognitive function in adult cardiothoracic transplant candidates and recipients. J Cardiovasc Nurs 2005; 20 (5 Suppl.): S74-87
22. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6 (5): 522-31
23. Szende A, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health 2005; 8 (5): 534-48
24. Cupples S, Dew MA, Grady KL, et al. Report of the Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation: present status of research on psychosocial outcomes in cardiothoracic transplantation. Review and recommendations for the field. J Heart Lung Transplant 2006; 25 (6): 716-25
25. Grady KL, Lanuza DM. Physical functional outcomes after cardiothoracic transplantation. J Cardiovasc Nurs 2005; 20 (5 Suppl.): S43-50
26. Hathaway D, Winsett R, Prendergast M, et al. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens. Clin Transplant 2003; 17 (3): 183-94
27. Hricik DE, Halbert RJ, Barr ML, et al. Life satisfaction in renal transplant recipients: preliminary results from the transplant learning center. Am J Kidney Dis 2001; 38 (3): 580-7
28. Matas AJ, Halbert RJ, Barr ML, et al. Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transplant 2002; 16 (2): 113-21
29. Siegal B, Halbert RJ, McGuire MJ. Life satisfaction among kidney transplant recipients: demographic and biological factors. Prog Transplant 2002; 12 (4): 293-8
30. Napolitano MA. Development of a pulmonary-specific quality of life scale (PQLS). Ann Behav Med 1999; 21: S168
31. Napolitano MA, Babyak MA, Palmer S, et al. Effects of a telephone-based psychosocial intervention for patients awaiting lung transplantation. Chest 2002; 122 (4): 1176-84
32. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 Suppl. B: 25-31
33. Younossi ZM, McCormick M, Price LL, et al. Impact of liver transplantation on health-related quality of life. Liver Transpl 2000; 6 (6): 779-83
34. Belle SH, Porayko MK, Hoofnagle JH, et al. Changes in quality of life after liver transplantation among adults. Liver Transpl Surg 1997; 3 (2): 93-104
35. Barotfi S, Molnar MZ, Almasi C, et al. Validation of the Kidney Disease Quality of Life-Short Form questionnaire in kidney transplant patients. J Psychosom Res 2006; 60 (5): 495-504
36. Kim WR, Lindor KD, Malinchoc M, et al. Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology 2000; 32 (5): 924-9
37. Laupacis A, Pus N, Muirhead N, et al. Disease-specific questionnaire for patients with a renal transplant. Nephron 1993; 64 (2): 226-31
38. Park H, Bang WR, Kim SJ, et al. Quality of life of ESRD patients: development of a tool and comparison between transplant and dialysis patients. Transplant Proc 1992; 24 (4): 1435-7
39. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45 (2): 295-300
40. Ferrer M, Cordoba J, Garin O, et al. Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl 2006; 12 (1): 95-104
41. Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 3 (5): 329-38
42. Karam V, Castaing D, Danet C, et al. Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. Liver Transpl 2003; 9 (7): 703-11
43. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003; 76 (12): 1699-704
44. Jacobs RJ, Pescovitz MD, Brook B, et al. A self-administered quality of life questionnaire for renal transplant recipients. Nephron 1998; 79 (1): 123-4
45. Rebollo P, Ortega F, Ortega T, et al. Spanish validation of the "kidney transplant questionnaire": a useful instrument for assessing health related quality of life in kidney transplant patients. Health Qual Life Outcomes 2003; 1 (1): 56
46. MacNaughton KL, Rodrigue JR, Cicale M, et al. Health-related quality of life and symptom frequency before and after lung transplantation. Clin Transplant 1998; 12 (4): 320-3
47. Moons P, De Geest S, Versteven K, et al. Psychometric properties of the "Modified Transplant Symptom Occurrence and Symptom Distress Scale". J Nurs Meas 2001; 9 (2): 115-34
48. Moons P, Vanrenterghem Y, Van Hooff JP, et al. Health-related quality of life and symptom experience in tacrolimus-based regimens after renal transplantation: a multicentre study. Transpl Int 2003; 16 (9): 653-64
49. Winsett RP, Arheart K, Stratta RJ, et al. Evaluation of an immunosuppressant side effect instrument. Prog Transplant 2004; 14 (3): 210-6, 40
50. Matthees BJ, Anantachoti P, Kreitzer MJ, et al. Use of complementary therapies, adherence, and quality of life in lung transplant recipients. Heart Lung 2001; 30 (4): 258-68
51. De Vito DA, Hoffman LA, Dauber JH, et al. Evaluating the reliability and validity of the Questionnaire for Lung Transplant Patients. Prog Transplant 2002; 12 (3): 191-8
52. De Vito DA, Kim Y, Vensak J, et al. Validation and refinement of the Questionnaire for Lung Transplant Patients. Prog Transplant 2004; 14 (4): 338-45
53. Unal G, de Boer JB, Borsboom GJ, et al. A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 2001; 54 (6): 587-96
54. Franke GH, Reimer J, Kohnle M, et al. Quality of life in end-stage renal disease patients after successful kidney transplantation: development of the ESRD symptom checklist. Transplantation module. Nephron 1999; 83 (1): 31-9
55. Grady KL, Jalowiec A, Grusk BB, et al. Symptom distress in cardiac transplant candidates. Heart Lung 1992; 21 (5): 434-9
56. Leventhal H, Johnson JE. Laboratory and field experimentation: development of a theory of self-regulation. In: Wooldridge PJ, Schmitt MH, Skipper JK, editors. Behavioral science and nursing theory. St. Louis (MO): CV Mosby, 1983: 189-262
57. Rhodes VA, Watson PM. Symptom distress: the concept. Past and present. Semin Oncol Nurs 1987; 3 (4): 242-7
58. De Geest S, Moons P. The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients. Nephrol Dial Transplant 2000; 15 (4): 457-9
59. Jalowiec A, Grady KL, White-Williams C, et al. Symptom distress three months after heart transplantation. J Heart Lung Transplant 1997; 16 (6): 604-14
60. Grady KL, Jalowiec A, White-Williams C. Patient compliance at one year and two years after heart transplantation. J Heart Lung Transplant 1998; 17 (4): 383-94
61. Ziegelmann JP, Griva K, Hankins M, et al. The Transplant Effects Questionnaire (TxEQ): the development of a questionnaire for assessing the multidimensional outcome of organ transplantation. Example of end stage renal disease (ESRD). Br J Health Psychol 2002; 7 (Pt 4): 393-408
62. Griva K, Ziegelmann JP, Thompson D, et al. Quality of life and emotional responses in cadaver and living related renal transplant recipients. Nephrol Dial Transplant 2002; 17 (12): 2204-11
63. Jalowiec A, Grady KL, White-Williams C. Stressors in patients awaiting a heart transplant. Behav Med 1994; 19 (4): 145-54
64. Kong IL, Molassiotis A. Quality of life, coping and concerns in Chinese patients after renal transplantation. Int J Nurs Stud 1999; 36 (4): 313-22
65. Weinert C, Tilden VP. Measures of social support: assessment of validity. Nurs Res 1990; 39 (4): 212-6
66. Weinert C. A social support measure: PRQ85. Nurs Res 1987; 36 (5): 273-7
67. Brandt PA, Weinert C. The PRQ: a social support measure. Nurs Res 1981; 30 (5): 277-80
68. Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998; 66 (12): 1718-26
69. Chisholm MA, Lance CE, Williamson GM, et al. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Educ Couns 2005; 59 (1): 13-20
70. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006 Mar; 41 (3): 385-92
71. Chisholm MA, Lance CE, Williamson GM, et al. Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrol Dial Transplant 2005; 20 (1): 181-8
72. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998; 17 (9): 854-63
73. Schafer-keller P, Steiger J, Denhaerynck K, et al. Using electronic monitoring as reference standard: how well do state of measurement methods measure medication adherence in kidney transplant recipients? American Transplant Congress. Am J Transplant 2005; 5: s331
74. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16 (2): 269-77
75. Feurer ID, Moore DE, Speroff T, et al. Refining a health-related quality of life assessment strategy for solid organ transplant patients. Clin Transplant 2004; 18 Suppl. 12: 39-45
76. Grady KL, Jalowiec A, White-Williams C, et al. Heart transplant candidates' perception of helpfulness of health care provider interventions. Cardiovasc Nurs 1993; 29 (5): 33-7
77. US Food and Drug Administration, Department of Health and Human Services. Guidance for industry: patient-reported outents. come measures. Use in medical product development to support labeling claims: draft guidance [online]. Available from URL: http://www.fda.gov/cder/guidance/5460dft.pdf [Ac-cessed 2007 Mar 7]
78. Tell GS, Mittelmark MB, Hylander B, et al. Social support and health-related quality of life in black and white dialysis patients. ANNA J 1995; 22 (3): 301-8; discussion 9-10
79. Shidler NR, Peterson RA, Kimmel PL. Quality of life and psychosocial relationships in patients with chronic renal insufficiency. Am J Kidney Dis 1998; 32 (4): 557-66
80. Payne JL, Feurer ID, Pinson CW. Quality of life as part of outcomes analysis in solid organ transplantation. Inside Case Management 2001; 8 (5): 9-11
81. Cowling T, Jennings LW, Goldstein RM, et al. Liver transplantation and health-related quality of life: scoring differences between men and women. Liver Transpl 2004; 10 (1): 88-96
82. Cowling T, Jennings LW, Jung GS, et al. Comparing quality of life following liver transplantation for Laennec's versus non-Laennec's patients. Clin Transplant 2000; 14 (2): 115-20
83. Whiting JF. Standards for economic and quality of life studies in transplantation. Transplantation 2000; 70 (7): 1115-21
84. Younossi ZM, Guyatt G. Quality-of-life assessments and chronic liver disease. Am J Gastroenterol 1998; 93 (7): 1037-41
85. Greenstein SM, Siegal B. Postrenal transplant health beliefs and ethnicity: the Compliance Study Group. Transplant Proc 1997; 29 (8): 3741-2
86. Bandura A. The explanatory and predictive scope of self-efficastudy. cy theory. J Clinical Soc Psychol 1986; 4: 359-73